Alirocumab vs Enlicitide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Weak signal

NCT01507831 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07477704 (registry estimate)

Reported efficacy

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)

Result source: NCT03510884

Enlicitide · Lipfendra

Marketed by Merck & Co.

Phase 3 in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT05952856 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.

Next expected readout: November 2027 · NCT07821944 (registry estimate)

Reported efficacy

Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)

Result source: NCT05952856

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlirocumabEnlicitide
LDL-C, % change-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
Non-HDL-C, % change-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
ApoB, % change-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
Lp(a), % change-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
3-point MACE (% with event)—Not posted · NCT04790513—Not posted · NCT07216482

LDL-C, % change

Alirocumab
-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
Enlicitide
-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126

Non-HDL-C, % change

Alirocumab
-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Enlicitide
-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126

ApoB, % change

Alirocumab
-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Enlicitide
-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126

Lp(a), % change

Alirocumab
-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Enlicitide
-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366

3-point MACE (% with event)

Alirocumab
—Not posted · NCT04790513
Enlicitide
—Not posted · NCT07216482
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Alirocumab: 5 of 5 rows · Enlicitide: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumabEnlicitide
Rows use multiple source trials
LDL-C Goal Attainment
responder rate · % of participants
80.7% (n=1530) vs 8.5% (n=780) placebo @ 24wk150 mg Q2Wa,b,c,d,e
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more dose
82.8% (n=1523) vs 8.5% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk30 mga,b,c,d,e
NCT05261126 · Phase 2 · registry result, not featured evidence
show 3 more doses
90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
85.5% (n=76) vs 9.3% (n=75) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
80.5% (n=77) vs 9.3% (n=75) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
Dropout rate
28.3%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
40.3%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
25.4%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
23.8%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
n/a: no completion milestone75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
12.8%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
28.1%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
16.7%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
21.6%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
25.5%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
15.4%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
0%150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
5.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.7%Q4W
NCT03510884 · Phase 3
22%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
15.5%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
0%
NCT02938949 · Phase 4 · registry result, not featured evidence
9.6%
NCT02984982 · Phase 4 · registry result, not featured evidence
11.2%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
12%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
5.7%New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
6.6%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
8.7%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
15.3%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
23.8%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9.6%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
10.3%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
8.3%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
22.4%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
24.1%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
19.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
19.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
41.3%
NCT01576484 · Phase 2 · registry result, not featured evidence
—20 mgg
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
3%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
1%Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
7.3%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
4.2%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
6.2%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
4%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
3%75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.4%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
8.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
4.9%150 mg Q2W
NCT02326220 · Phase 3
9.2%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
9.6%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
0%Q4W
NCT03510884 · Phase 3
3.8%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
6.2%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
—
NCT02938949 · Phase 4 · registry result, not featured evidence
4.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
3.6%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
4.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
1.5%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.5%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.5%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
18.3%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
2.1%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.9%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
3.7%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8.8%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.3%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
—300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
2.2%
NCT01576484 · Phase 2 · registry result, not featured evidence
—20 mgg
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
—
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Serious AEs
18.7%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
—150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
13.9%150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
12.6%75 /up to 150 mg Q2W
NCT01644175 · Phase 3
—75/150 mg Q2W
NCT01644175 · Phase 3
13.7%75/Up to 150 mg Q2W
NCT01623115 · Phase 3
—75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6%75 mg/up to 150 mg
NCT01709500 · Phase 3
11.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
11.3%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
3.4%150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—75 /up to 150 mg Q2W
NCT01644188 · Phase 3
25.9%75/Up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644474 · Phase 3
1.9%75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
8.7%Q2W
NCT03510884 · Phase 3
6.1%Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
23.3%Alirocumab
NCT01663402 · Phase 3
17.4%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
40%
NCT02938949 · Phase 4 · registry result, not featured evidence
18.4%
NCT02984982 · Phase 4 · registry result, not featured evidence
9.5%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
16.2%
NCT02476006 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
10.1%75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.6%150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
22%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
29.2%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
26.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
29.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
12.1%150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.1%75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
9.5%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
17.5%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7%75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
—75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.4%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
2.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
16.7%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
17.4%
NCT01576484 · Phase 2 · registry result, not featured evidence
9.9%20 mgg
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
4.5%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
3.9%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
1.3%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
150 mg Q2Wf
nasopharyngitis 13.5% (placebo 13.1%)
upper respiratory tract infection 7.4% (placebo 8.6%)
injection site reaction 5.9% (placebo 4.2%)
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 60 more results
150 Q2W
nasopharyngitis 13.9% (placebo 11.4%)
influenza 12.5% (placebo 2.9%)
injection site reaction 8.3% (placebo 5.7%)
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75 /up to 150 mg Q2W
upper respiratory tract infection 7.7% (placebo 10.3%)
nasopharyngitis 7.2% (placebo 4.7%)
urinary tract infection 6.3% (placebo 3.7%)
NCT01644175 · Phase 3
75/Up to 150 mg Q2W
injection site reaction 12.4% (placebo 11%)
nasopharyngitis 11.2% (placebo 7.4%)
upper respiratory tract infection 6.8% (placebo 8.6%)
NCT01623115 · Phase 3
75 mg/up to 150 mg
influenza 14.4% (placebo 7.4%)
injection site reaction 10.8% (placebo 7.4%)
nasopharyngitis 10.8% (placebo 19.8%)
NCT01709500 · Phase 3
300 mg Q4W/Up 150 mg Q2W
injection site reaction 16.2% (placebo 7%)
upper respiratory tract infection 9% (placebo 7.9%)
nasopharyngitis 8.5% (placebo 7.9%)
NCT01926782 · Phase 3
75 mg Q2W/Up 150 mg Q2W
injection site reaction 8.7% (placebo 7%)
nasopharyngitis 8.7% (placebo 7.9%)
upper respiratory tract infection 7% (placebo 7.9%)
NCT01926782 · Phase 3
150 mg Q2W
fatigue 14.6% (placebo 9.5%)
myalgia 12.2% (placebo 4.8%)
diarrhoea 9.8% (placebo 0%)
NCT02326220 · Phase 3
150 mg Q2W
anaemia 6.9% (placebo 0%)
nasopharyngitis 3.4% (placebo 9.5%)
arthralgia 0% (placebo 9.5%)
NCT02326220 · Phase 3
75/Up to 150 mg Q2W
accidental overdose 9.8%
upper respiratory tract infection 8.8%
hypertension 6.5%
NCT01644188 · Phase 3
75/Up150 mg Q2W
nasopharyngitis 23.1%
diarrhoea 11.5%
influenza 11.5%
NCT01644474 · Phase 3
150 Q2W
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
Q2W
nasopharyngitis 14.3% (placebo 8%)
headache 6.1% (placebo 8%)
injection site reaction 6.1% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 7.7% (placebo 8%)
upper respiratory tract infection 5.8% (placebo 12%)
injection site reaction 3.8% (placebo 0%)
NCT03510884 · Phase 3
Q2W
headache 10.9% (placebo 8%)
oropharyngeal pain 8.7% (placebo 0%)
injection site reaction 6.5% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 14.3% (placebo 8%)
covid-19 8.2% (placebo 0%)
nasopharyngitis 6.1% (placebo 8%)
NCT03510884 · Phase 3
Q2W
low density lipoprotein decreased 8% (placebo 0%)
nasopharyngitis 8% (placebo 8%)
nausea 8% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 16% (placebo 8%)
covid-19 4% (placebo 0%)
injection site reaction 4% (placebo 0%)
NCT03510884 · Phase 3
nasopharyngitis 6% (placebo 5.6%)
hypertension 5.7% (placebo 6.1%)
myalgia 5.5% (placebo 5.3%)
NCT01663402 · Phase 3
75 Q2W/Up150 Q2W
nasopharyngitis 7.5% (placebo 8.2%)
headache 6.5% (placebo 7.8%)
hypertension 5.9% (placebo 6.7%)
NCT02957682 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
injection site reaction 6.8%
back pain 5.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
urinary tract infection 5.5%
diarrhoea 5.1%
arthralgia 2.2%
NCT02642159 · Phase 4 · registry result, not featured evidence
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.8%
myalgia 7.1%
headache 6.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.1%
arthralgia 6.1%
contusion 3%
NCT03415178 · Phase 3 · registry result, not featured evidence
urinary tract infection 6.1%
arthralgia 4.5%
contusion 1.5%
NCT03415178 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up150 mg Q2W
upper respiratory tract infection 13.3%
accidental overdose 6.7%
NCT02715726 · Phase 3 · registry result, not featured evidence
150 mg Q2W
viral upper respiratory tract infection 15.1% (placebo 16.1%)
non-cardiac chest pain 7.5% (placebo 1.8%)
back pain 1.9% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 14.8% (placebo 16.1%)
pharyngitis 5.6% (placebo 0%)
back pain 0% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up Q2W
viral upper respiratory tract infection 34.2% (placebo 16.1%)
fall 7% (placebo 5.4%)
back pain 5.1% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
75 or 150 mg Q2W
viral upper respiratory tract infection 14.2%
upper respiratory tract infection 10.8%
influenza 9.3%
NCT01954394 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 18.8% (placebo 5.2%)
back pain 14.6% (placebo 0%)
injection site reaction 14.6% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 15.1% (placebo 5.2%)
fall 13.2% (placebo 1.7%)
diarrhoea 10.4% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
cough 17.6% (placebo 0%)
arthralgia 15.7% (placebo 6.9%)
osteoarthritis 15.7% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up150 mg Q2W
injection site reaction 13.8% (placebo 0%)
arthralgia 12.1% (placebo 6.9%)
headache 8.6% (placebo 6.9%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up150 mg Q2W
headache 8.7% (placebo 6.9%)
viral upper respiratory tract infection 8.7% (placebo 5.2%)
muscle spasms 7.8% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg/ up to 150 mg
myalgia 24.6%
nasopharyngitis 6.3%
upper respiratory tract infection 5.6%
NCT01709513 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
nasopharyngitis 4.9% (placebo 5.3%)
NCT02585778 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
dizziness 6.2% (placebo 2.9%)
nasopharyngitis 6.2% (placebo 3.9%)
diarrhoea 5.2% (placebo 1%)
NCT02289963 · Phase 3 · registry result, not featured evidence
75 mg/ Up to 150 mg Q2W
nasopharyngitis 45.5% (placebo 36.1%)
back pain 12.6% (placebo 5.6%)
injection site reaction 12.6% (placebo 4.2%)
NCT02107898 · Phase 3 · registry result, not featured evidence
75 mg/up to 150 mg + 10 mg
arthralgia 8.2%
nausea 6.1%
nasopharyngitis 4.1%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + 20 mg
myalgia 7.4%
upper respiratory tract infection 7.4%
injection site reaction 5.6%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 20 mg
muscle spasms 7%
back pain 5.3%
arthralgia 3.5%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 40 mg
back pain 8.5%
nasopharyngitis 8.5%
accidental overdose 6.4%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
300 mg Q4W
acne 20%
diarrhoea 20%
influenza like illness 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
nasopharyngitis 20%
pyogenic granuloma 20%
upper respiratory tract infection 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
abdominal discomfort 16.7%
diarrhoea 16.7%
epistaxis 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
ligament sprain 11.1%
nasopharyngitis 11.1%
abdominal pain 5.6%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
animal scratch 16.7%
arthropod bite 16.7%
blood follicle stimulating hormone decreased 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q4W
abdominal pain 16.7%
asthma 16.7%
depressed mood 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
50 mg Q2W
diarrhoea 33.3%
nasopharyngitis 33.3%
alcohol abuse 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
gastroenteritis viral 30%
ear infection 10%
headache 10%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
pharyngitis 25%
abdominal discomfort 0%
abdominal pain 0%
NCT02890992 · Phase 2 · registry result, not featured evidence
30 mg Q2W
ear infection 25%
epistaxis 25%
fall 25%
NCT02890992 · Phase 2 · registry result, not featured evidence
viral upper respiratory tract infection 40%
acne 20%
blood bilirubin increased 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
gastroenteritis 33.3%
viral upper respiratory tract infection 33.3%
abdominal discomfort 16.7%
NCT01604824 · Phase 2 · registry result, not featured evidence
headache 28.6%
acne 14.3%
angina pectoris 14.3%
NCT01604824 · Phase 2 · registry result, not featured evidence
abdominal discomfort 20%
abdominal distension 20%
acne 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 28.3%
nasopharyngitis 23.9%
bronchitis 21.7%
NCT01576484 · Phase 2 · registry result, not featured evidence
g
nasopharyngitis 9.4% (placebo 7.9%)
influenza 8.4% (placebo 8.9%)
accidental overdose 7.9% (placebo 4%)
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 9 more results
20 mg
accidental overdose 0%
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
30 mg
covid-19 5.3% (placebo 9.3%)
arthralgia 2.6% (placebo 1.3%)
nausea 2.6% (placebo 0%)
NCT05261126 · Phase 2 · registry result, not featured evidence
18 mg
covid-19 6.6% (placebo 9.3%)
nausea 5.3% (placebo 0%)
diarrhoea 3.9% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
12 mg
dyspepsia 6.6% (placebo 1.3%)
arthralgia 5.3% (placebo 1.3%)
fatigue 3.9% (placebo 6.7%)
NCT05261126 · Phase 2 · registry result, not featured evidence
6 mg
covid-19 7.8% (placebo 9.3%)
diarrhoea 6.5% (placebo 1.3%)
dyspepsia 1.3% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
dry mouth 12.5%
hypertension 12.5%
animal bite 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 12.5%
orthostatic hypotension 12.5%
dry mouth 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 24 weeks versus 8 weeks.
  6. fPopulation comparability has not been reviewed for 82 of these studies.
  7. gPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Total-C -33.3% (n=144) vs -1.9% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 36 more results
-35.8% (n=308) vs -0.8% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.4% (n=144) vs -1% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-32.9% (n=308) vs -0.1% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.8% (n=1530) vs -0.3% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-38.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-29.3% (n=467) vs -14.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-29.4% (n=467) vs -15.1% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-32.3% (n=58) vs 3% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-24.5% (n=58) vs 1.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.4% (n=322) vs 7.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-28.3% (n=322) vs 4.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-30.6% (n=166) vs 2.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-26.6% (n=166) vs 3.4% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-32.5% (n=37) vs -1.9% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-30% (n=76) vs -0.8% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33.4% (n=37) vs -1% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-26.5% (n=76) vs -0.1% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-34% (n=115) vs 3% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-32.6% (n=115) vs 1.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.8% (n=126) vs -10.9% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-39.5% (n=143) vs 2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-41.1% (n=143) vs -2.1% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-28.9% (n=48) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-20.6% (n=53) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29% (n=48) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-19.4% (n=53) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-27.1% (n=55) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-33.6% (n=46) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=55) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=46) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29.6% (n=1058) vs -0.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-31.8% (n=1058) vs 1.5% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29.6% (n=1058) vs 1.1% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29% (n=1058) vs 1.1% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-26.5% (n=1058) vs 1.8% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-32.7% (n=126) vs -11.6% (n=122) Ezetimibe @ 12wk75/ up to 150
NCT01709513 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 70 62% (n=144) vs 3.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 43 more results
80.4% (n=308) vs 10.9% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
70.4% (n=141) vs 2.1% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.8% (n=302) vs 10.8% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
79.3% (n=1530) vs 8% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
81.2% (n=1523) vs 8% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75% (n=205) vs 9% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
77.5% (n=204) vs 8% (n=105) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
77% (n=467) vs 45.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
78.9% (n=464) vs 47.4% (n=235) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
59.4% (n=52) vs 2.4% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
50% (n=58) vs 0% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
50.9% (n=57) vs 0% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
59.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
60.1% (n=321) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
68.2% (n=166) vs 1.2% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
68.8% (n=166) vs 1.3% (n=81) placebo @ 52wk75 mg/up to 150 mg
NCT01709500 · Phase 3
57.7% (n=37) vs 3.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
74.4% (n=76) vs 10.9% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
61.7% (n=37) vs 2.1% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
77.4% (n=75) vs 10.8% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
85.1% (n=403) vs 40.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
87% (n=401) vs 42.1% (n=204) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
60% (n=115) vs 0% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
61.7% (n=115) vs 0% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
32.5% (n=126) vs 0.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
39% (n=123) vs 0.8% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
70.2% (n=49) vs 5.1% (n=24) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
76.4% (n=284) vs 5.1% (n=24) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
85.8% (n=97) vs 14.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
88.8% (n=97) vs 14.1% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
77.8% (n=48) vs 31.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
60.1% (n=53) vs 31.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
76.5% (n=48) vs 34.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
66.1% (n=51) vs 34.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
79.2% (n=55) vs 16% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
77.2% (n=46) vs 16% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
82.3% (n=52) vs 20% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
83.7% (n=46) vs 20% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
69.4% (n=1058) vs 10.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
74.7% (n=1058) vs 8.4% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
71.4% (n=1058) vs 10.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
69.7% (n=1058) vs 11.3% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
64.5% (n=1058) vs 10.7% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
HDL-C 2.5% (n=144) vs -5.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 62 more results
3.6% (n=308) vs -1.5% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=144) vs -0.9% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.7% (n=308) vs 0.4% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4% (n=1530) vs -0.6% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
5.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
3.5% (n=205) vs -3.8% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
6.7% (n=205) vs -2.4% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
9.3% (n=41) vs 4% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
10.9% (n=41) vs 2.4% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
8.6% (n=467) vs 0.5% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
8.7% (n=467) vs 2.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
6% (n=52) vs 1.6% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
9% (n=52) vs 1.6% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
7.7% (n=54) vs 2% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
9.9% (n=53) vs 2% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.7% (n=58) vs -2.4% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.6% (n=58) vs -0.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6.4% (n=322) vs 2.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6% (n=166) vs -0.8% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
6% (n=166) vs -0.8% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-0.1% (n=37) vs -5.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=76) vs -1.5% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.5% (n=37) vs -0.9% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
7.6% (n=76) vs 0.4% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
14.5% (n=273) vs 8.2% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
8.3% (n=403) vs 6.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
7.3% (n=403) vs 6.1% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
7.4% (n=115) vs -2.4% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.8% (n=115) vs -0.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.7% (n=126) vs 6.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9% (n=126) vs 7.6% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
11.2% (n=49) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
8.1% (n=287) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
13.8% (n=97) vs 6.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7.1% (n=97) vs 2% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7.9% (n=143) vs 2.1% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.7% (n=143) vs -1.8% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
9.1% (n=48) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.2% (n=53) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.9% (n=48) vs 0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8% (n=53) vs 0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=55) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
7.7% (n=46) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.1% (n=55) vs -3.2% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
8.5% (n=46) vs -3.2% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
3.5% (n=49) vs -2.2% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
4% (n=50) vs -2.2% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
3.5% (n=49) vs -2.2% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
4% (n=50) vs -2.2% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
5.9% (n=1058) vs 0.6% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
9% (n=1058) vs 3.8% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
9.2% (n=1058) vs 3.8% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
10.3% (n=1058) vs 4.4% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
10.8% (n=1058) vs 5.5% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
21.04% (n=93) vs 12.19% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Fasting Triglycerides -15.6% (n=1530) vs 1.8% (n=780) placebo @ 24wk150 mg Q2W
percent change · % of baseline
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-16.7% (n=1530) vs 1.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1 5.2% (n=138) vs -1.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 59 more results
5.5% (n=292) vs 2.9% (n=146) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4.6% (n=138) vs -1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=292) vs 2.7% (n=146) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4% (n=1468) vs 1.2% (n=753) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
4.6% (n=1468) vs 0.6% (n=753) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
3.3% (n=185) vs -2.5% (n=96) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
3.8% (n=185) vs -1.8% (n=96) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
4.2% (n=41) vs 0% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
7.8% (n=41) vs -0.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
5% (n=452) vs -1.3% (n=228) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
1.5% (n=467) vs -2.9% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
4.7% (n=48) vs -0.6% (n=46) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
2.3% (n=48) vs -2.2% (n=46) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
6.8% (n=54) vs 2.9% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
9.1% (n=53) vs 2.9% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
10% (n=58) vs 3.4% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.6% (n=58) vs 2.6% (n=56) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5% (n=309) vs 0.3% (n=160) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.9% (n=309) vs 0.1% (n=160) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.8% (n=163) vs -1.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
0.4% (n=163) vs -1.9% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
3.1% (n=34) vs -1.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.5% (n=75) vs 2.9% (n=146) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.4% (n=34) vs -1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.1% (n=75) vs 2.7% (n=146) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
3.2% (n=398) vs -0.2% (n=203) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.7% (n=398) vs 1.1% (n=203) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
8.2% (n=112) vs 3.4% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5.9% (n=112) vs 2.6% (n=56) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
4.8% (n=122) vs 2.9% (n=116) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
5.5% (n=122) vs 3.9% (n=116) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 3.2% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 1.5% (n=100) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
1.4% (n=141) vs -2.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
1.5% (n=141) vs -4.8% (n=71) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.7% (n=44) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
6.7% (n=49) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.3% (n=44) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
9.1% (n=49) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.6% (n=53) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.8% (n=42) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.4% (n=53) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
9.4% (n=42) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
1.7% (n=1058) vs -1.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
6.1% (n=1058) vs 2.9% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.7% (n=1058) vs 4.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.8% (n=1058) vs 4.4% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.5% (n=1058) vs 4.2% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
11.75% (n=92) vs 4.61% (n=88) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Total Cholesterol -27.9% (n=205) vs -2.9% (n=106) placebo @ 24wk75/150 mg Q2W
percent change · % of baseline
NCT01644175 · Phase 3
show 25 more results
-25.4% (n=205) vs 0.9% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-36.4% (n=41) vs 3.1% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
-27.1% (n=41) vs 4.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
-29.6% (n=52) vs -10.9% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-30.3% (n=52) vs -12% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-25.8% (n=54) vs -3.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-44.7% (n=53) vs -3.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-27.4% (n=273) vs -2.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-33.9% (n=403) vs -13.8% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-34.2% (n=403) vs -14.9% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-29.9% (n=49) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-26.8% (n=287) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-31.2% (n=97) vs 4% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-32.9% (n=97) vs 2.8% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-25.3% (n=49) vs 7.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-27% (n=50) vs 7.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-25.3% (n=49) vs 7.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-27% (n=50) vs 7.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-35.43% (n=93) vs -7.59% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Fasting TG -13.4% (n=144) vs -1.5% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 53 more results
-15.2% (n=308) vs -0.1% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-12.3% (n=144) vs 1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13.1% (n=308) vs 0.5% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6% (n=205) vs -5.4% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-11.3% (n=205) vs 3% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-11.9% (n=52) vs -10.8% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-12.2% (n=52) vs -2.3% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-0.6% (n=54) vs -6.4% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-18% (n=53) vs -6.4% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-9.2% (n=58) vs 1.1% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-3% (n=58) vs 2.1% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.6% (n=322) vs 6.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-8% (n=322) vs 1.7% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-10.4% (n=166) vs 0.5% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-8.1% (n=166) vs 0.6% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-9.8% (n=37) vs -1.5% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6.7% (n=76) vs -0.1% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-18.3% (n=37) vs 1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-7.3% (n=76) vs 0.5% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13% (n=273) vs -8.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-14.462% (n=403) vs -14.409% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-9.965% (n=403) vs -13.585% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-10.6% (n=115) vs 1.1% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-11.3% (n=115) vs 2.1% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.3% (n=126) vs -3.6% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-8% (n=126) vs -9.4% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-13.6% (n=49) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-5.7% (n=287) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-8.143% (n=97) vs -3.627% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-6.999% (n=97) vs 2.113% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-15.3% (n=143) vs 6.7% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-13.1% (n=143) vs 2.4% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-11.2% (n=48) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-8.7% (n=53) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-14% (n=48) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-10.1% (n=53) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-12% (n=55) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-19.1% (n=46) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.4% (n=55) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.1% (n=46) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-18.37% (n=93) vs -8.85% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
LDL-C Target Achievement 78.9% (n=144) vs 9.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 7 more results
85.2% (n=308) vs 22.2% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
88.6% (n=141) vs 11.3% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
89.5% (n=302) vs 22.5% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.9% (n=37) vs 9.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
82.5% (n=76) vs 22.2% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
93% (n=37) vs 11.3% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
86.4% (n=75) vs 22.5% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
Apheresis Treatment 0.128 vs 0.806 placebo Treatments @ 18wk150 mg Q2W
absolute change · Treatments
NCT02326220 · Phase 3
show 1 more result
0.165 vs 0.774 placebo Treatments @ 18wk150 mg Q2W
NCT02326220 · Phase 3
LDL-C 30 Reduction 95.1% (n=41) vs 4.8% (n=21) placebo @ 6wk150 mg Q2W
responder rate · % of participants
NCT02326220 · Phase 3
show 10 more results
65.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
57.1% (n=45) vs 4.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
LDL-C 50 Reduction 63.4% (n=41) vs 0% (n=21) placebo @ 6wk150 mg Q2W
responder rate · % of participants
NCT02326220 · Phase 3
show 1 more result
43.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
W-BQ22 0.91 vs -1.43 placebo score @ 18wk150 mg Q2W
absolute change · score
NCT02326220 · Phase 3

+ 88 further endpoints in the CSV export.

Enlicitide

LDL-C Less Than 70 and 50% Reduction 70.8% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
81.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 5.5 and 50 Pct Reduction 67.3% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
78.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Enlicitide's landscape